X4
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 2/28/2025
Pipeline by Phase
Therapeutic Focus
Clinical Trials (11)
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Started: 6/6/2024
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Started: 10/24/2019
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Started: 12/1/2016
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Started: 2/28/2025
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Started: 10/16/2021
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
Started: 4/27/2016
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Started: 4/30/2020
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
Started: 12/7/2016
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
Started: 9/15/2016
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
Started: 1/12/2016